Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - The report reviews Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) Overview 6 Therapeutics Development 7 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Stage of Development 7 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Therapy Area 8 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Indication 9 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Companies 13 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Universities/Institutes 15 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 24 Bristol-Myers Squibb Company 24 Daiichi Sankyo Company, Limited 25 Galapagos NV 26 Merrimack Pharmaceuticals, Inc. 27 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Drug Profiles 28 Antisense RNAi Oligonucleotide to Inhibit EPHA2 for Solid Tumor and Ovarian Cancer - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 dasatinib - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 DS-8895 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 GLPG-1790 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 MM-310 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Monoclonal Antibodies to Activate EPHA2 for Oncology - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Dormant Projects 36 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Discontinued Products 37 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Featured News & Press Releases 38 Jun 09, 2016: Bristol-Myers Squibb to Present Data on Sprycel (dasatinib) at the 21st Congress of the European Hematology Association 38 Apr 21, 2016: Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting 38 Mar 16, 2016: Merrimack to Present on MM-310 at the 2016 American Association for Cancer Research Annual Meeting 39 Aug 13, 2015: FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase 40 Jul 06, 2015: Delhi High Court Upholds BMS' Patent For Dasatinib 41 Jun 29, 2015: Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment 42 Nov 07, 2014: Bristol-Myers Squibb Announces Oral Presentations of Sprycel at 56th Annual American Society for Hematology (ASH) Meeting 43 Oct 19, 2014: DIPP Seeks Information On Dasatinib For Issuance Of Compulsory Licences 43 May 07, 2014: India Seeks Waiver Of Bristol-Myers Squibb's Patent Rights For Dasatinib 44 Mar 18, 2014: Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego 44 Dec 09, 2013: Four-Year Data from Phase 3 DASISION Trial Comparing Sprycel (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Presented at Annual Meeting of the American Society of Hematology 45 Jun 20, 2013: Bristol-Myers And Otsuka Announce FDA Approval For US Product Labeling Update For Sprycel 46 Apr 22, 2013: Galapagos Discovers New Drug Candidate To Treat Breast Cancer 48 Mar 20, 2013: Moffitt Cancer Center Researchers Study Use of Dasatinib for Patients with High-Risk MDS 49 Mar 19, 2013: BDR Pharma Applies For Compulsory License To Sell Generic Version Of Bristol-Myers Squibb's Cancer Drug Dasatanib In India 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by Bristol-Myers Squibb Company, H1 2016 24 Pipeline by Daiichi Sankyo Company, Limited, H1 2016 25 Pipeline by Galapagos NV, H1 2016 26 Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 27 Dormant Projects, H1 2016 36 Discontinued Products, H1 2016 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
